NCIC Clinical Trials Group

Members / Participants Membership Information Clinical Trials Meetings
&
Education
Publications

Lectures
Correlative Science / Tumour Bank Notices Fellowships Committees Papaya Mango EDC BARL

2013

Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

20 Dec 2013

General

Happy Holidays and Happy New Year!!!!
On behalf of Canadian Cancer Trials Group's Central Office, we would like to wish everyone a very Merry Christmas, Happy Holidays, and Happy New Year.
Read more ....

Canadian Cancer Trials Group Bulletin in 2014
The first Bulletin of 2014 will be sent on Friday, January 10, 2014.
Read more ....

Group Administrators Office

Canadian Cancer Trials Group Holiday Closure
The Canadian Cancer Trials Group Central Office will be closed with limited staff over the holidays. Web-based applications (i.e. MANGO, GCP) will be available. Please see the Canadian Cancer Trials Group website ... http://www.ctg.queensu.ca ... for complete information.
Read more ....

Recent Publications
There were three recent publications -- 2 related to Canadian Cancer Trials Group CO.17 and the other related to Canadian Cancer Trials Group MAC.4 (IBCSG 24-02) and Canadian Cancer Trials Group MAC.5 (IBCSG 25-02).
Read more ....

Canadian Cancer Trials Group Annual Spring Meeting of Participants
SAVE THE DATE -- The Canadian Cancer Trials Group 2014 Annual Spring Meeting of Participants will be held May 2-4, 2014 at the Eaton Chelsea Hotel (formerly The Delta Chelsea Hotel) in Toronto.
Read more ....

Office of Compliance and Oversight

Ethics Contact Email Change - CER@ctg.queensu.ca
The Office of Compliance and Oversight (OCO) is pleased to announce that Canadian Cancer Trials Group will begin using a centralized Ethics email address, CER@ctg.queensu.ca, for all Ethics communication.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

06 Dec 2013

EDC - Rave

Electronic Data Capture (Medidata Rave) Maintenance
On Saturday December 7th from 0900h-1100h EST
Electronic Data Capture (Medidata Rave) will be shut down temporarily for maintenance
Read more ....

Group Administrators Office

Recent Publication
There was one recent publication related to Canadian Cancer Trials Group MA.12.
Read more ....

Office of Compliance and Oversight

CTEP Transitioning SAE Reporting from AdEERS to CTEP-AERS
CTEP has recently announced the beginning of the gradual transition of SAE reporting from AdEERS to CTEP-AERS. By March 1, 2014, it is expected that all users will have transitioned to CTEP-AERS for trials using AdEERS but NOT using Medidata Rave.
Read more ....

Trial Management Group

Trials Closed to Accrual
Two Canadian Cancer Trials Group-led trials were recently closed to accrual -- IND.193 and IND.212.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

22 Nov 2013

General

Maria Ricci Memorial Lectureship in Medical Oncology
Dr. Frances Shepherd is this year's guest speaker for the Maria Ricci Memorial Lectureship in Medical Oncology being held December 5, 2013 at 4:30 pm at Queen's University.
Read more ....

Recent Publications
There were four recent publications, two reporting primary results -- Canadian Cancer Trials Group IND.181 and Canadian Cancer Trials Group LY.11 (SWOG S9704) -- and two other "general" publications.
Read more ....

ECOG-ACRIN Laboratories Thanksgiving Holiday Schedule
Please note the following holiday schedule for ECOG-ACRIN Laboratories.
Read more ....

San Antonio Breast Cancer Symposium
One abstract - related to Canadian Cancer Trials Group MA.22 -- is being presented at the 36th Annual San Antonio Breast Cancer Symposium being held December 10-14, 2013 in San Antonio, Texas.
Read more ....

American Society of Hematology Annual Meeting
Several Canadian Cancer Trials Group-related abstracts, including one reporting primary results of Canadian Cancer Trials Group LY.12, will be presented at the 55th American Society of Hematology Annual Meeting and Exposition being held December 7-10, 2013 in New Orleans.
Read more ....

Group Administrators Office

Single-Study Centres and DSMC Summary Reports
Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy.
Read more ....

7 Days in May Contributes $31,255 to Canadian Cancer Trials Group
The 7 Days in May Foundation donated $31,255, funds raised during its annual bike ride around Lake Ontario, to the Canadian Cancer Trials Group in support of pancreatic cancer research.
Read more ....

Membership Roster

Roster Office Reminders
With the upcoming Christmas Break, centres are encouraged to update trial Participant Lists and to request website, MANGO, and EDC access prior to December 13, 2013.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

08 Nov 2013

General

Recent Publication
There were one recent publication reporting results of an analysis of archival tumour samples taken from women with recurrent or metastatic endometrial cancer who participated on Canadian Cancer Trials Group IND.160, IND.160B and IND.192.
Read more ....

Trial Management Group

CRA Executive Committee Looking for Volunteers
The Clinical Research Associates Executive Committee is seeking a CRA representative for the Clinical Research Associates Executive Committee.
Read more ....

Trial Activation
We are pleased to inform you that Canadian Cancer Trials Group PR.15, Randomized Phase II Feasibility Trial of Image Guided External Beam Radiotherapy With or Without High Dose Rate Brachytherapy Boost in Men with Intermediate-Risk Prostate Cancer, was activated November 5.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

25 Oct 2013

Group Administrators Office

Leadership of the Sarcoma Site Committee
Drs. Thierry Alcindor and Torsten Nielsen will be taking over the reins of the Canadian Cancer Trials Group's Sarcoma Disease Site Committee from Dr. Vivien Bramwell who has retired after leading the Committee for the past 28 years!
Read more ....

Recent Publications
The primary results of two Canadian Cancer Trials Group IND trials -- IND.181 and IND.203 -- have recently been published. Additionally, the quality of life analysis for CO.20, as well as a paper associated with Canadian Cancer Trials Group HD.6, have also recently been published.
Read more ....

Maria Ricci Memorial Lectureship in Medical Oncology
Dr. Frances Shepherd is this year's guest speaker for the Maria Ricci Memorial Lectureship in Medical Oncology being held December 5, 2013 at 4:30 pm at Queen's University.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

11 Oct 2013

Group Administrators Office

Canadian Cancer Trials Group Central Office Closure
The Canadian Cancer Trials Group Central Office will be closed Monday, October 14, 2013 for Thanksgiving.
Read more ....

Canadian Cancer Trials Group OV.18 Presented at ECC2013
The results of Canadian Cancer Trials Group OV.18 (ICON6), an international randomized, double-blind, academic clinical phase III trial of cediranib, were recently presented as part of the media programme at the 2013 European Cancer Congress in Amsterdam.
Read more ....

Trial Management Group

Trial Closed to Accrual
Canadian Cancer Trials Group CE.6 (EORTC 26062-22061) trial has reached its targeted accrual of 560 patients and was closed to accrual on October 1, 2013.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Special Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Special Bulletin

01 Oct 2013

Group Administrators Office

US Government Shutdown
Essential services will be supported during the shutdown. Canadian Cancer Trials Group conduct and partnership with US cooperative groups on clinical trials should be unaffected at this time. Specific information from various offices and branches has been provided.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

27 Sep 2013

Group Administrators Office

Four Canadian Cancer Trials Group Members Inducted as Fellows of the CAHS
Four members of the Canadian Cancer Trials Group, including the Group's Interim Director, Dr. Elizabeth Eisenhauer, were recently inducted as fellows of the Canadian Academy of Health Sciences. The other members include Drs Carolyn Gotay, Rita Kandel and Michael Pollak.
Read more ....

Office of Compliance and Oversight

Bryn Fisher, Manager, Office of Compliance and Oversight
We are very pleased to announce that as of September 16, 2013, Ms. Bryn Fisher has taken over responsibilities as Manager of the Office of Compliance and Oversight (OCO) at the Canadian Cancer Trials Group's Central Office.
Read more ....

Changes to Ethics Research Associate Centre Assignments
Canadian Cancer Trials Group member centres should note that their Central Office Ethics Research (ER) Associate may have changed. Please visit the ER Associate Centre Assignment page: http://www.ctg.queensu.ca/private/compliance/ethics/centre_assignments.html for an updated listing.
Read more ....

Trial Management Group

Canadian Cancer Trials Group MY.10 Permanently Closed
Canadian Cancer Trials Group MY.10 has been permanently closed and no longer requires action, including patient follow-up for trial purposes, completion of Case Report Forms and annual REB re-approvals.
Read more ....

Trials Closed to Accrual
Canadian Cancer Trials Group BRC.2 (ECOG 1505) and Canadian Cancer Trials Group BRC2.E were closed to accrual on September 20, 2013.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

13 Sep 2013

General

Recent Publications
There were two recent publications both reporting primary results -- Canadian Cancer Trials Group-led BR.19 and BR.16 (ECOG 5597).
Read more ....

Office of Compliance and Oversight

New Unblinding Procedures
The Office of Compliance and Oversight is adding a new section to the websites of double-blinded trials where unblinding information is posted in order for it to be found quickly and easily in the event of an emergency.
Read more ....

Trial Management Group

Trial Activation
Canadian Cancer Trials Group ALC.3 (SWOG 1203) was centrally activated on September 10, 2013.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

30 Aug 2013

General

Canadian Cancer Trials Group Central Office Holiday Closure
The Canadian Cancer Trials Group Central Office will be closed on Monday, September 2, 2013 for Labour Day. Regular business hours will resume on Tuesday, September 3 at 8:00 am EDT.
Read more ....

Recent Publications
There were two recent publications -- one related to Canadian Cancer Trials Group BR.14 and the other related to IND.160.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

16 Aug 2013

General

Correlative Studies and Tissue Banking
An article published in CMAJ discussing the issue of tissue ownership, designation of research vs diagnostic tissue, and patients' role and rights has prompted a response from the Canadian Cancer Trials Group's CSTB and Lay Representatives Committees.
Read more ....

Recent Publication
There was one recent publication related to Canadian Cancer Trials Group BR.21 - A Randomized Placebo Controlled Study of OSI-774 (Tarceva) in Patients with Incurable Stage IIIB/IV Non-Small Cell Lung Cancer Who Have Failed Standard Therapy for Advanced or Metastatic Disease.
Read more ....

UPDATE from the Canadian Cancer Trials Group Interim Director's Desk
Dr. Elizabeth Eisenhauer, Interim Director of the Canadian Cancer Trials Group, took up her position on July 29, 2013. After two weeks on the job, Dr. Eisenhauer would like to update you on Group activities and plans for the coming months.
Read more ....

Trial Management Group

Trial Closed To Accrual
Canadian Cancer Trials Group IND.197 - Phase II Study of Foretinib in Patients with Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2) Negative, Recurrent/Metastatic Breast Cancer - was recently closed to accrual.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

02 Aug 2013

General

Recent Publication
There was one recent publication related to Canadian Cancer Trials Group MA.17 - A Phase III Randomized Double Blind Study of Letrozole versus Placebo in Women with Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen.
Read more ....

Group Administrators Office

Search for Canadian Cancer Trials Group Director
The search for the next Director of the Canadian Cancer Trials Group and Edith and Carla Eisenhauer Chair in Clinical Cancer Research is underway. Please click here to view a full description of the position.
Read more ....

Holiday Closure
The Canadian Cancer Trials Group will be closed on Monday, August 5, 2013 for the Civic Holiday. Regular business hours will resume on Tuesday, August 6 at 8:00 am EDT.
Read more ....

Trial Management Group

Trial Activation
We are pleased to announce that Canadian Cancer Trials Group GA.1 (TROG 0808) - A Randomized Phase II/III Study of Preoperative Chemotherapy versus Preoperative Chemotherapy for Resectable Gastric Cancer - was centrally activated July 31, 2013.
Read more ....

Trial Activation
We are pleased to announce activation of IND.212 - A Pilot Study of Imetelstat Given Intravenously on Day 1 and 8 of a 21 Day Schedule alone and With Standard 13-cis-retinoic acid in Children with Recurrent and/or Refractory Neuroblastoma.
Read more ....

Trial Closed to Accrual
Canadian Cancer Trials Group BR.28 (MLG CONVERT) has met its accrual goal and was closed to further accrual as of July 22, 2013.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Special Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Special Bulletin

26 Jul 2013

General

Dr. Ralph Meyer
Dr. Ralph Meyer is stepping down as Director of the Canadian Cancer Trials Group effective today and Dr. Elizabeth Eisenhauer will be assuming the role of Interim Director on Monday, July 29. Please "View Special Bulletin" for a personal message of thanks and farewell from Dr. Meyer.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

19 Jul 2013

SPECIAL ANNOUNCEMENT

Search Committee Established for Director of Canadian Cancer Trials Group
A Search Committee has been established to provide a recommendation on the appointment of a successor to Dr. Ralph Meyer. Please click "read more" below to view the membership of the committee and for instructions on submitting nominations.
Read more ....

Office of Compliance and Oversight

Expedited Reporting of Adverse Events to CTEP via AdEERS
CTEP often receives Adverse Event Expedited Reporting System (AdEERS) reports for adverse events that do not meet the criteria for expedited reporting. Please review the following information to reduce site and CTEP staff time and administrative costs.
Read more ....

Trial Management Group

CRA Volunteers Needed
The Canadian Cancer Trials Group Clinical Research Associates Executive Committee (CRAEC) is actively seeking CRA representatives to sit on the following Committees -- Hematology Executive, Genitourinary Executive and the Quality of Life Committee.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

05 Jul 2013

Trial Management Group

CRA Volunteers Needed
The Canadian Cancer Trials Group Clinical Research Associates Executive Committee (CRAEC) is actively seeking CRA representatives to sit on the following Committees -- Hematology Executive, Genitourinary Executive and the Quality of Life Committee.
Read more ....

Trial Closed to Accrual
The Canadian Cancer Trials Group MA.34/Aphinity study (BIG 4-11) was closed to further accrual on June 28, 2013.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

28 Jun 2013

General

Appointment of Canadian Cancer Trials Group Group Administrator
The Canadian Cancer Trials Group Central Office is very pleased to announce that Alison Urton has been appointed as the Group Administrator and will assume this role as of July 1, 2013.
Read more ....

Canadian Cancer Trials Group Holiday Closure
The Canadian Cancer Trials Group will be closed on Monday, July 1, 2013 for Canada Day. Regular business hours will resume on Tuesday, July 2 at 8:00 am EDT.
Read more ....

Recent Publications
There were three recent publications -- one reporting primary results of Canadian Cancer Trials Group ALC.1 (SWOG 0106), one a general statistical paper, and the other reporting outcomes of the NCI's Operational Efficiencies Working Group recommendations.
Read more ....

2013 Spring Meeting Event -- Cosbie Lecture
Dr. Elizabeth Eisenhauer's presentation, "Initiatives to Advance the State of Cancer Clinical Trials in Canada - Hope in Spring" is posted online. Dr. Eisenhauer was the "Cosbie Lecturer" at the 2013 Spring Meeting recently held in Toronto.
Read more ....

ECOG Coordinating Centre Holiday Closure
The ECOG Coordinating Center will be closed on Thursday July 4th, 2013, in observance of Independence Day.
Read more ....

Trial Management Group

Trial Activation
Canadian Cancer Trials Group LY.16 (LYSARC Relevance Trial) was centrally activated on June 17, 2013.
Read more ....

ECOG Pathology Coordinating Office
The ECOG Pathology Coordinating Office (PCO) will be closed on Thursday, July 4th, but will have skeleton crews available.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

10 Jun 2013

General

Spring Meeting 2013 Expense Claim Forms
If you received a full-funded invitation to the 2013 Spring Meeting of Participants, please read the following carefully ...
Read more ....

New Investigator Clinical Trials Course
The next Canadian Cancer Trials Group New Investigator Clinical Trials Course, scheduled for August 21-23, 2013 at the Donald Gordon Centre at Queen's University in Kingston, is now accepting applications.
Read more ....

Canadian Cancer Trials Group SC.20 and ASCO
Dr. Edward Chow presented results of Canadian Cancer Trials Group SC.20 at the recent American Society of Clinical Oncology Annual Meeting. Results of the trial were highlighted in the ASCO News the next day and was the subject of media reports.
Read more ....

Recent Publication
The primary results of Canadian Cancer Trials Group IND.199 - A Phase II Study of Temsirolimus (NSC 683864), an mTOR Inhibitor, in Patients with Recurrent, Unresectable, Locally Advanced or Metastatic Carcimona of the Cervix - was recently published.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

07 Jun 2013

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

06 Jun 2013

General

Spring Meeting 2013 Expense Claim Forms
If you received a full-funded invitation to the 2013 Spring Meeting of Participants, please read the following carefully ...
Read more ....

New Investigator Clinical Trials Course
The next Canadian Cancer Trials Group New Investigator Clinical Trials Course, scheduled for August 21-23, 2013 at the Donald Gordon Centre at Queen's University in Kingston, is now accepting applications.
Read more ....

Canadian Cancer Trials Group SC.20 and ASCO
Dr. Edward Chow presented results of Canadian Cancer Trials Group SC.20 at the recent American Society of Clinical Oncology Annual Meeting. Results of the trial were highlighted in the ASCO News the next day and was the subject of media reports.
Read more ....

Recent Publication
The primary results of Canadian Cancer Trials Group IND.199 - A Phase II Study of Temsirolimus (NSC 683864), an mTOR Inhibitor, in Patients with Recurrent, Unresectable, Locally Advanced or Metastatic Carcimona of the Cervix - was recently published.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

24 May 2013

General

Recent Publications
There were two recent publications -- one reporting primary results of Canadian Cancer Trials Group-led CO.20, and the other related to Canadian Cancer Trials Group BR.10.
Read more ....

ASCO 2013
A number of abstracts related to Canadian Cancer Trials Group trials or trials which included Canadian Cancer Trials Group participation are being presented at the American Society of Clinical Oncology Annual Meeting in Chicago, May 31 - June 4, 2013.
Read more ....

Health Related Quality of Life Outcomes Survey
The Quality of Life Committee is asking for oncologist members of Canadian Cancer Trials Group Site Committees to participate in a survey looking at health-related quality of life outcomes in phase III clinical trials. Deadline to complete the survey is May 31, 2013.
Read more ....

CCCTN and Canadian Participating Centres
The Canadian Cancer Trials Group encourages all of its Canadian member centres to support the recently-announced Canadian Partnership Against Cancer initiative -- the Canadian Cancer Clinical Trials Network.
Read more ....

Single-Study Centres and DSMC Summary Reports
Trial-specific Data Safety Monitoring Committee Summary Reports are now posted on trial-specific websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards, if required by local policy.
Read more ....

Trial Management Group

Permanent Trial Closure - Intergroup-Led Trials
Based on the Canadian Cancer Trials Group's recent trial status survey, lead groups have indicated that three trials in which the Canadian Cancer Trials Group participates can be permanently closed.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

10 May 2013

General

Health Related Quality of Life Outcomes Survey
The Quality of Life Committee is asking for oncologist members of Canadian Cancer Trials Group Site Committees to participate in a survey looking at health-related quality of life outcomes in phase III clinical trials.
Read more ....

Recent Publications
There were 5 recent publications -- an Canadian Cancer Trials Group BR.10 / LACE-Bio publication, primary results from Canadian Cancer Trials Group CM.1, the primary results of Canadian Cancer Trials Group HD.7. a correlative science paper related to Canadian Cancer Trials Group MA.12, and one related to Canadian Cancer Trials Group MA.27.
Read more ....

Canadian Cancer Trials Group Holiday Closure
The Canadian Cancer Trials Group will be closed on Monday, May 20, 2013 to celebrate Victoria Day. Regular business hours will resume on Tuesday, May 21 at 8:00 am EDT.
Read more ....

Spring Meeting 2013 Expense Claim Forms
When sending in your Spring Meeting 2013 Expense Claim Form, please be sure to read the Travel Policy carefully to help ensure your claims are processed as quickly and efficiently as possible. Incomplete or inadequate claims will be returned.
Read more ....

Investigational New Drug (IND) Program Recognition Awards
The Canadian Cancer Trials Group is very pleased to announce that two inaugural Investigational New Drug Program awards named after Dr. Elizabeth Eisenhauer, past Director of the IND Program, were presented at the Canadian Cancer Trials Group's recent Annual Spring Meeting of Participants.
Read more ....

Canadian Cancer Trials Group Spring Meeting: Claiming CME Credits
The 2013 Annual Spring Meeting of Participants is an Accredited Group Learning Activity (Section 1) of the Royal College of Physicians and Surgeons of Canada. Meeting participants may be eligible to receive CME credits.
Read more ....

Office of Compliance and Oversight

Ethics Application FAQ Available for CO.23 and LY.15
In an effort to assist centres with their local REB applications, the OCO has posted trial-specific Ethics Application Frequently Asked Questions documents to the CO.23 and LY.15 trial websites.
Read more ....

Trial Management Group

Trial Activation
Canadian Cancer Trials Group LY.15 - A Phase I Study of Romidepsin, Gemcitabine, Dexamethasone and Cisplatin Combination Therapy in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma - was recently activated.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

26 Apr 2013

General

2013 Spring Meeting of Participants -- Wireless Internet
For 2013, we have arranged for free wireless internet to be available in the meeting rooms and in Churchill Court of the Delta Chelsea Hotel. Access will be available to all participants for the duration of Spring Meeting.
Read more ....

2013 Spring Meeting Trial Reports
The 2013 Spring Meeting Trial Reports are posted on the Canadian Cancer Trials Group members-only website using this link ... http://www.ctg.queensu.ca/trials/.
Read more ....

Canadian Cancer Trials Group Fellow Receives Research Program Award
Dr. Ravi Ramjeesingh, Fellow with the Canadian Cancer Trials Group, has been awarded the Canadian Institutes of Health Research (CIHR)/Rx&D Canadian Association of Medical Oncologists (CAMO) Research Program Fellowship Award.
Read more ....

Leadership of Canadian Cancer Trials Group Genitourinary Site Committee
Drs Kim Chi and Neil Fleshner have been named as the new co-chairs of the Canadian Cancer Trials Group's Genitourinary (GU) Disease Site Committee.
Read more ....

OICR Named as Lead to Develop Coordinating Centre for New CCCTN
Led by Dr. Janet Dancey, the Ontario Institute for Cancer Research (OICR) has been selected by the Canadian Partnership Against Cancer to develop the coordinating centre for the Canadian Cancer Clinical Trials Network.
Read more ....

Office of Compliance and Oversight

Records Retention
The Office of Compliance and Oversight (OCO), in conjunction with the Trial Management Group (TMG), are pleased to announce an updated list of trials for which records no longer need to be retained.
Read more ....

Trial Management Group

Trial Activation
Canadian Cancer Trials Group Trial CO.23 -- A Phase III Randomized Study of BBI608 and Best Supportive Care versus Placebo and Best Supportive Care in Patients with Pretreated Advanced Colorectal Carcinoma -- was activated on April 15, 2013.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

17 Apr 2013

General

Important Notice from Dr. Ralph Meyer
After 7 years as Director of the Canadian Cancer Trials Group, Dr. Ralph Meyer will be stepping down to take on a role with Hamilton Health Sciences and Cancer Care Ontario. Please click on "View Special Bulletin" above.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

12 Apr 2013

General

2013 Spring Meeting Event -- Cosbie Lecture
We are very pleased to announce Dr. Elizabeth Eisenhauer as the 2013 "Cosbie Lecturer". The title of Dr. Eisenhauer's talk is "Initiatives to Advance the State of Cancer Clinical Trials in Canada - Hope in Spring."
Read more ....

Recent Publications
There were four recent publications, including one from the LACE-Bio consortium and one reporting primary results of Canadian Cancer Trials Group PR.8 (SWOG 9346) -- both in NEJM -- one related to Canadian Cancer Trials Group CRC.2 (NCCTG 0147), and a general methodological paper.
Read more ....

2013 Annual Spring Meeting of Participants
The Canadian Cancer Trials Group 2013 Annual Spring Meeting of Participants will be held April 26 - 28, 2013 at the Delta Chelsea Hotel in Toronto. A draft schedule is available.
Read more ....

Office of Compliance and Oversight

Implementation of Modifications Requiring a CTA-A
The Office of Compliance and Oversight has updated its policy regarding implementation of modifications requiring a Clinical Trial Application Amendment (CTA-A) with Health Canada.
Read more ....

Trial Management Group

Trial Closed to Accrual
Canadian Cancer Trials Group CE.5 (EORTC 22033-26033) - Primary Chemotherapy with Temozolomide vs. Radiotherapy in Patients with Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study - was closed to accrual on April 11.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

28 Mar 2013

General

Holiday Closure
The Canadian Cancer Trials Group will be closed on Friday, March 29, 2013 in observance of Good Friday. Regular business hours will resume on Monday, April 1 at 8:00 am EDT.
Read more ....

Recent Publication
There was one recent publication related to Canadian Cancer Trials Group MAC.3 (ECOG E2100).
Read more ....

Navigating the Bulletin
Do Bulletin items seem to you to be too brief? If so, PLEASE don't forget to click on "View This Week's Bulletin" at the top of the email. You'll then see a "read more" link that will take you to complete information about each item.
Read more ....

Trial Management Group

CRA Volunteer Needed for Gynecology Site Commmittee
The Clinical Research Associates Executive Committee (CRAEC) is actively seeking a CRA representative for the Canadian Cancer Trials Group Gynecology Disease Site Committee (DSC) Executive.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

15 Mar 2013

Office of Compliance and Oversight

CRA Volunteer Needed for Gynecology Site Commmittee
The Clinical Research Associates (CRA) Executive Committee is actively seeking a CRA representative for the Canadian Cancer Trials Group Gynecology Site Committee Executive.
Read more ....

Trial Management Group

Trial Closed to Accrual
Canadian Cancer Trials Group IND. 198 - Phase I/II Study of Foretinib in Combination with Lapatinib in Patients with Human Epidermal Growth Factor Receptor 2 (HER2) Over-Expressing Metastatic Breast Cancer - was closed to accrual on March 5, 2013.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

01 Mar 2013

General

Recent Publications
There were two recent publications -- one published in the European Journal of Cancer, and the other published in the Journal of Biopharmaceutical Statistics.
Read more ....

Maria Ricci Memorial Lectureship in Medical Oncology
Dr. Mark Levine, Director of the Ontario Clinical Oncology Group (OCOG), is this year's guest speaker for the Maria Ricci Memorial Lectureship in Medical Oncology being held March 21, 2013 at 4:00 pm at the Cancer Research Institute, Queen's University.
Read more ....

2013 Spring Meeting of Participants
The Canadian Cancer Trials Group 2013 Annual Spring Meeting of Participants will be held April 26-28, 2013 at the Delta Chelsea Hotel in Toronto. Funded and non-funded invitations have now all been sent.
Read more ....

PA.6 and Pancreatic Cancer Canada
The Canadian Cancer Trials Group and Pancreatic Cancer Canada have teamed up to promote awareness of Canadian Cancer Trials Group PA.6.
Read more ....

Trial Management Group

NCI US PMB Change of Address and Phone Numbers
Effective March 25, 2013 the NCI US Pharmaceutical Management Branch (PMB) will be moving. This affects the following trials as drug is currently distributed by the NCI US PMB - CL.3, CM.1, MDC.1, CRC.6, HEC.1, NEC.2, and BRC.2.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

15 Feb 2013

General

Maria Ricci Memorial Lectureship in Medical Oncology
Dr. Mark Levine, Director of the Ontario Clinical Oncology Group (OCOG), is this year's guest speaker for the Maria Ricci Memorial Lectureship in Medical Oncology being held March 21, 2013 at 4:00 pm at the Cancer Research Institute, Queen's University.
Read more ....

Recent Publications
There were two recent publications, including one reporting quality of life outcomes from Canadian Cancer Trials Group OV.19 (MRC ICON7).
Read more ....

2013 Spring Meeting of Participants
The Canadian Cancer Trials Group 2013 Annual Spring Meeting of Participants will be held April 26-28, 2013 at the Delta Chelsea Hotel in Toronto. Full-funded and non-funded invitations have now been sent. Meeting Participants should review their invitations carefully.
Read more ....

Office of Compliance and Oversight

Updated CTMB Guidelines: New Pharmacy Review Requirement
To ensure compliance with the updated NCI US CTMB Guidelines, Canadian Cancer Trials Group's Compliance Group has implemented new requirements related to pharmacy review.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

01 Feb 2013

General

Recent Publication
The final results of Canadian Cancer Trials Group MA.27 - A Randomized Phase III Trial of Exemestane versus Anastrozole in Postmenopausal Women with Receptor Positive Primary Breast Cancer - were recently published online in JCO.
Read more ....

2013 Spring Meeting of Participants
The Canadian Cancer Trials Group 2013 Annual Spring Meeting of Participants will be held April 26-28, 2013 at the Delta Chelsea Hotel in Toronto. Full-funded invitations will be sent next week.
Read more ....

Membership Roster

Participants List Change Form
The Canadian Cancer Trials Group Participants List Change Form (PLCF) has been revised to include Effective Start / Stop Dates for each trial role. This allows sites to plan changes to qualified site personnel.
Read more ....

Trial Management Group

Trial Closed to Accrual
Canadian Cancer Trials Group IND.196 - A Phase I/II Study of Foretinib in Patients with Previously Treated Non-Small Cell Lung Cancer Receiving Standard Erlotinib Therapy - was closed to accrual on January 24, 2013.
Read more ....

Trial Activation
Canadian Cancer Trials Group IND.215 - A Phase Ib Study of Selumetinib in Patients with Previously Treated or Untreated Advanced/Metastatic NSCLC who are Receiving Standard Chemotherapy Regimens - was centrally activated on January 30, 2013.
Read more ....

Canadian Cancer Trials Group MA.32 Closed to North American Accrual
The Canadian Cancer Trials Group is very pleased to announce that MA.32 - A Phase III Randomized Trial of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer - has reached its target accrual of 3582 patients.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

18 Jan 2013

General

2013 Spring Meeting of Participants
The Canadian Cancer Trials Group 2013 Annual Spring Meeting of Participants will be held April 26-28, 2013 at the Delta Chelsea Hotel in Toronto.
Read more ....

New Investigator Clinical Trials Course
The next Canadian Cancer Trials Group New Investigator Clinical Trials Course is scheduled for August 21-23, 2013 at the Donald Gordon Centre at Queen's University in Kingston.
Read more ....

Recent Publication
The final results of Canadian Cancer Trials Group MY.10 - A Randomized Phase III Study of Thalidomide and Prednisone as Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma - were recently published online in Blood.
Read more ....

Trial Management Group

2013 Permanent Trial Closure - Canadian Cancer Trials Group-Led Trials
The Canadian Cancer Trials Group's Trial Management Group has now completed the annual Permanent Trial Closure assessment for Canadian Cancer Trials Group-led studies. A total of 9 trials have been permanently closed.
Read more ....

Trial Closed to Accrual
Canadian Cancer Trials Group AL.5 (DFCI 06-254) - A Phase II Study of Adult ALL Trial - was closed to accrual after meeting its accrual goal of 112 registered patients.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

15 Jan 2013

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletin

Canadian Cancer Trials Group

Canadian Cancer Trials Group Bulletin

07 Jan 2013

General

CCS Listing of Top 10 Cancer Stories of 2012
The results of two Canadian Cancer Trials Group-related clinical trials were included in the Canadian Cancer Society's listing of the top 10 cancer stories of 2012.
Read more ....

Recent Publication
Final results of Canadian Cancer Trials Group IND.186 were recently published in the journal Leukemia & Lymphoma.
Read more ....

You are receiving this Bulletin because of your involvement with the Canadian Cancer Trials Group. If you no longer wish to receive Canadian Cancer Trials Group Bulletins, please send an unsubscribe request by clicking here.

If you have any questions, comments or suggestions, please contact Canadian Cancer Trials Group Bulletin


Canadian Cancer Trials Group Bulletins